Effectiveness and Cost-Benefit of Influenza Vaccination of Healthy Working Adults

Abstract

Influenza vaccination of healthy working adults younger than 65 years can reduce the rates of ILI, lost workdays, and physician visits during years when the vaccine and circulating viruses are similar, but vaccination may not provide overall economic benefits in most years. JAMA. 2000;284:1655-1663.

Predictors of yearly influenza vaccination in hospitalized and community based patients

“…Reasons for not vaccinating are similar between the primary and secondary care in our study, main reason being fear of side effects with 39.3% in the primary and 36.7% in the secondary setting. This is also similar to the other Maltese study with 43% giving this reason [ 8 ]. Other reasons not to vaccinate in our study were unaware of indication (15.6% MDH and 40.5% community) forgot/ had no time (22.1% MDH and 13.1% community), feel they do not need to take it or that it doesn’t work (20% MDH and 6% community) and history of contraindication to vaccinate (5.6% MDH and 1.2% community).…”

Rapid Licensure of a New, Inactivated Influenza Vaccine in the United States

“…An important observation in the current study was that the rates of systemic symptoms after vaccination, such as headache, fatigue, chills and fever, were not different in vaccine and placebo recipients. This is consistent with multiple other reports, [8][9][10][11] and is an important verification that inactivated influenza vaccines do not result in influenza-like illnesses, although this is a frequent concern of recipients. Additionally, the proportion of individuals having one or more adverse events during the study was similar between vaccine and placebo groups and there was no statistically significant evidence that any unsolicited adverse event occurred more frequently among vaccine recipients compared to controls.…”

Antibody Response to Influenza Vaccination in Healthy Adults

“…The results of the present study confirmed findings of other authors that influenza vaccine is highly immunogenic in healthy adults (3,4,19,38). Unfortunately, there are no data on the economic analysis of influenza vaccination in this group in Poland.…”